Insulet
$131.69Change from previous close: +0.69%Absolute change: +$0.90
Valuation
Data as of October 4, 2026
Valuation multiples
- Market cap
- $9.09B
- Enterprise value
- $9.48B
- P/E (trailing 12 months)
- 24.5
- Forward P/E
- 17.0
- PEG
- 1.03
- Price/book
- 6.39
- Price/sales
- 2.98
- EV/EBITDA
- 15.4
- EV/revenue
- 3.11
Profitability and growth
- Gross margin
- 71.1%
- Operating margin
- 16.2%
- Net margin
- 12.3%
- ROE
- 26.0%
- ROA
- 9.7%
- ROIC
- 21.3%
- Revenue growth (year over year)
- 23.5%
- Earnings growth (year over year)
- 328.6%
Financial health
- Total cash
- $534.9M
- Total debt
- $948.4M
- Debt/equity
- 0.67
- Current ratio
- 2.49
- Quick ratio
- 1.51
- Altman Z-Score
- 8.46
- Piotroski F-Score
- 8.00
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $171.91
- Median price target
- $167.50
- High price target
- $275.00
- Low price target
- $144.00
- Analysts with a price target
- 22
- Consensus
- Buy
- Forward EPS
- $7.72
- EPS estimate, current year
- $6.50
Shares and trading
- Beta
- 1.08
- Average volume
- 1.63M
- Shares outstanding
- 69.35M
- Float
- 69.06M
- Institutional ownership
- 107.0%
- Insider ownership
- 0.3%
- Short interest (% of float)
- 8.3%
- Short ratio (days)
- 2.86